Clinical Trials Logo

Clinical Trial Summary

Background: Potent antithrombotic therapy has improved prognosis for patients with acute myocardial infarction (MI) significantly, however, at a price of increased bleeding risk. Helicobacter pylori (H. pylori) infection commonly causes upper gastrointestinal bleeding (UGIB). If systematic screening for H. pylori and subsequent eradication therapy significantly reduces the risk of UGIB and improves outcomes is unknown. Study design: A cluster randomized, cross-over, registry-based clinical trial using nationwide Swedish registries for patient enrollment and data collection. Population: Patients hospitalized for MI at up to 40 hospitals across Sweden. Regional PCI networks comprise 18 clusters. Clusters will be randomized to H. pylori screening or no screening for 1 year after which cross-over to the opposite strategy for 1 year is followed by 1-year follow-up. Intervention: All MI patients will be routinely screened for H. pylori. Patients diagnosed with active H. pylori infection will receive eradication therapy. All follow-up by data collection from national registries. Controls: Standard clinical practice. Data will be collected from national registries. Outcome: Primary outcome is the incidence of hospitalization for UGIB. Secondary outcomes include mortality (all-cause, cardiovascular), cardiovascular endpoints (rehospitalization for MI, heart failure or stroke), or UGIB requiring blood transfusion.


Clinical Trial Description

Background: Despite progressively reduced mortality over the last decades, cardiovascular disease remains the most common cause of death in both men and women in Sweden and the world. Ischemic heart disease with its acute presentation myocardial infarction (MI) accounts for the majority of cases, approximately 25000 hospitalized patients in Sweden annually. In addition to early revascularization therapy, potent antithrombotic therapy is the basis for the reduction in cardiovascular events, however, at a price of increased risk of bleeding, typically upper gastrointestinal bleeding (UGIB) that result in substantial morbidity, mortality, and medical care cost. Consequently, antithrombotic therapy may be interrupted in these cases leading to an excessive risk of cardiovascular events; in particular in patients with high age or comorbidities who - by fear of bleeding - rarely receive full recommended treatment from the start. It is recognized that major bleeding events affect prognosis comparably to spontaneous ischemic complications. To optimize the sensitive trade-off between ischemia and bleeding, risk factor management is crucial. On top of established risk factors - high age, male sex, smoking, dyslipidemia, hypertension, hyperglycemia, physical inactivity - chronic active infection with Helicobacter pylori (H. pylori) may be important for two reasons: First, as it commonly causes acute and chronic gastroduodenal lesions, concomitant anticoagulation or antithrombotic therapy aggravates the risk for bleeding, 2-fold with low dose aspirin, and 7-fold with dual antiplatelet therapy, which today is standard treatment for 12 months post MI.2 Non-invasive screening for H. pylori can be performed easily with high accuracy by urea breath test (UBT). If found positive, eradication by triple therapy is well established, recommended in risk individuals and believed to reverse the bleeding risk almost completely. Second, H. pylori has been proposed as a causal factor between atherosclerosis progression and plaque instability associated with a two-fold increased risk. However, as no data from contemporary randomized trials are available, controversy remains due to conflicting results caused by limitations in sample size, observational study design, lack of information on H. pylori virulence factors, and different methods of detection of H. pylori status. H. pylori may hence be an overlooked risk factor for bleeding complications in MI patients, which potentially could be eliminated by H. pylori eradication treatment. This would be anticipated not only to reduce the UGIB complications after MI but also to improve the adherence to dual antiplatelet therapy and consequently potentially also improve the cardiovascular prognosis in this group. H. pylori screening in a contemporary MI population has to our knowledge never been performed. Hence, it remains unknown if systematic screening and subsequent eradication therapy significantly reduces the risk of bleeding and improves prognosis. OBJECTIVE - paradigm and main hypothesis The aim of this main trial is to determine whether systematic screening for (H. pylori) and subsequent eradication therapy significantly reduces the risk of hospitalization for UGIB and cardiovascular events including death in patients after myocardial infarction (MI) The investigators hypothesize that H. pylori screening and eradication in MI patients tested positive reduces bleeding and improves cardiovascular outcomes. STUDY POPULATIONS: 1. PRIMARY INTENTION-TO-TREAT (ITT) POPULATION All patients 18 years of age or older registered in SWEDEHEART as admitted at an active study site and with a discharge diagnosis of MI (including ICD-10 code I21 or I22) irrespective of Hp diagnostics performed or possible eradication treatment if tested positive. 2. MATCHED SECONDARY PER-PROTOCOL (MPP) POPULATION All patients 18 years of age or older registered in SWEDEHEART as admitted at a study site randomized to screening and with a discharge diagnosis of MI (including ICD-10 code I21 or I22) who were screened for HP are compared to matched patients from the control group from study sites randomized to no-screening. 3. TERTIARY POPULATIONS 3.1 MATCHED SCREENED POPULATION (MS) All patients 18 years of age or older registered in SWEDEHEART as admitted at a study site randomized to screening and with a discharge diagnosis of MI (including ICD-10 code I21 or I22) who were screened positive for HP are compared to matched patients from the control group from study sites randomized to no-screening. 3.2 MATCHED TREATED POPULATION (MT) All patients 18 years of age or older registered in SWEDEHEART as admitted at a study site randomized to screening and with a discharge diagnosis of MI (including ICD-10 code I21 or I22) who were screened positive for HP and had eradication therapy dispensed are compared to matched patients from the control group from study sites randomized to no-screening. In matched populations, treatment effects will be estimated using latent subgroup methods based on randomization as an instrumental variable and respecting the cluster structure. OUTCOMES As specified below. Pre-specified subgroups are: - Age - Sex - Smoking status - Hypertension - Diabetes - Previous cardiovascular disease (MI, HF, stroke, peripheral arterial disease [PAD]) - Anemia (previous diagnosis and at arrival during index hospitalization) - Previous gastroduodenal disease (UGIB, peptic ulcer disease [PUD], atrophic gastritis, mucosa-associated lymphoid tissue [MALT] lymphoma, gastric cancer) - Chronic kidney disease (CKD) - MI patients by subtype - MI patients according to revascularization status - MI patients according to revascularization technique - Concomitant medication (antithrombotic, anticoagulation, NSAID, serotonin reuptake inhibitors, cortisone, proton pump inhibitors) - Stratified according to time on DAPT - Stratified according to antithrombotic therapy - Stratified according to trial site - Stratified according to socioeconomic and sociodemographic parameters All described endpoints will be analyzed in all subgroups and study populations and reported during short-term (30 days), medium-term (1,1-2,1-3 years) and, at a later stage, long-term (5 years, 10 years) follow-up (chapter 6). The primary analysis will use 1-2 years of follow-up. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05024864
Study type Interventional
Source Karolinska Institutet
Contact Robin Hofmann, MD, PhD
Phone +4681236161000
Email robin.hofmann@ki.se
Status Recruiting
Phase N/A
Start date November 17, 2021
Completion date January 17, 2030

See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04098172 - Evaluate the Performance and Safety of Comet Pressure Guidewire in the Measurement of FFR N/A